Companies · Pharmaceuticals

Spotlight Innovation, Inc.

West Des Moines · Pharmaceuticals

Diligence memoA one-page analyst read on Spotlight Innovation, Inc. — recommendation, valuation, rhythm, risks.
$44.1M
Total raised · real
4
Rounds
1.6×
Latest step-up
Top 22%
Sector rank · raised
Series C
Latest stage · inferred · Wed Aug 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Spotlight Innovation, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.02× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era.
Dormant
  • Last raise 9.8 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Spotlight Innovation, Inc. is one of 1613 Pharmaceuticals companies tracked from West Des Moines. By capital raised it ranks in the upper tier (ahead of 79% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
17
Investors (latest)
2016-08-31
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BPre-Seed · 2014-07-01 Raised $500K (real) Modeled valuation $24M (est)$500K$24MPre-Seed2014Series C · 2014-07-01 Raised $41M (real) Modeled valuation $1.5B (est)$41M$1.5BSeries C2014Series C · 2015-07-01 Raised $850K (real) Modeled valuation $30M (est)$850K$30MSeries C2015Series C · 2016-08-31 Raised $1.4M (real) Modeled valuation $48M (est)$1.4M$48MSeries C2016+$41M+$850K+$1.4MCumulative $44M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$500K · 2014
Series C$41.4M · 2014no Seed / Series A / Series B on file
Series C extension$850K · 2015
Series C extension$1.4M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$48.5M
Base estimate est.
$4.5M
Conservative case
$127.8M
Upside case
$9.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $23.7M · 2014-07-012014Series C · modeled $1.5B · 2014-07-01Series C · modeled $29.8M · 2015-07-01Series C · modeled $48.5M · 2016-08-312016
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
66%
Survival probability
49% low · 76% high
1.42×/yr
Annual markup
1.62×/yr upside case
6.0 yr
Elapsed time used
9.8 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$20.4M/yr
Capital velocity
12.0 yr
On record since
2014
First round
4
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 5.5× above median
This company$44.1M
Sector median$8.1M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.0× of median
This company$1.4M
Sector median$46.4M
Modeled value — vs sector median (estimate, all stages) 0.6× of median
This company$48.5M
Sector median$76.1M

Raised more than 79% of sector peers (real $). Modeled value above 43% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #32 of 32.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Amplyx Pharmaceuticals, Inc. · Series C Raised $116.6M · modeled $3.2B (est)Ligand Pharmaceuticals Inc · Series C Raised $85.4M · modeled $3.0B (est)Homology Medicines, Inc. · Series C Raised $127.1M · modeled $2.9B (est)KSQ Therapeutics, Inc. · Series C Raised $80.6M · modeled $2.8B (est)TP Therapeutics, Inc. · Series C Raised $126.4M · modeled $2.8B (est)Milestone Pharmaceuticals Inc. · Series C Raised $91.3M · modeled $2.8B (est)Aprecia Pharmaceuticals Co · Series C Raised $175.4M · modeled $2.8B (est)Tribute Pharmaceuticals Canada Inc. · Series C Raised $92.1M · modeled $2.6B (est)Aralez Pharmaceuticals Inc. · Series C Raised $75.0M · modeled $2.6B (est)Daisy Pharma Opioid Venture, LLC · Series C Raised $75.0M · modeled $2.6B (est)Forty Seven, Inc. · Series C Raised $109.1M · modeled $2.6B (est)MEI Pharma, Inc. · Series C Raised $76.1M · modeled $2.6B (est)Spotlight Innovation, Inc. (this company) Raised $44.1M · modeled $48.5M (est)Spotlight Innovation, Inc.
CompanyStageRaised · realValue · estvs peer med.
Amplyx Pharmaceuticals, Inc.Series C$116.6M$3.2B1.38×
Ligand Pharmaceuticals IncSeries C$85.4M$3.0B1.29×
Homology Medicines, Inc.Series C$127.1M$2.9B1.26×
KSQ Therapeutics, Inc.Series C$80.6M$2.8B1.22×
TP Therapeutics, Inc.Series C$126.4M$2.8B1.21×
Milestone Pharmaceuticals Inc.Series C$91.3M$2.8B1.21×
Aprecia Pharmaceuticals CoSeries C$175.4M$2.8B1.19×
Tribute Pharmaceuticals Canada Inc.Series C$92.1M$2.6B1.13×
Aralez Pharmaceuticals Inc.Series C$75.0M$2.6B1.13×
Daisy Pharma Opioid Venture, LLCSeries C$75.0M$2.6B1.13×
Forty Seven, Inc.Series C$109.1M$2.6B1.13×
MEI Pharma, Inc.Series C$76.1M$2.6B1.13×
Spotlight Innovation, Inc. this companySeries C$44.1M$48.5M0.02×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$500K2014-07-01$2.8M$23.7M85%
Series C$41.4M2014-07-01$276.1M$1.5B85%
Series C$850K2015-07-01$5.7M$29.8M85%
Series C$1.4M2016-08-31$9.2M$48.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$500K2014-07-01
    • First recorded raise — entered as Pre-Seed.
  2. Series C$41.4M2014-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 82.8× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 505).
  3. Series C$850K2015-07-01
    • Raised 12 mo later, in step with the ~13 mo sector norm.
    • Round 48.7× smaller than the prior — bridge or down round.
    • Switched to Rule 504 (was Rule 506(b)).
  4. Series C$1.4M2016-08-31
    • Raised 14 mo later, in step with the ~13 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 504).
    • 17 investors on this round.
Intelligence
2017 ~Q2
Modeled next raise · ~9mo cadence
$2.2M
Modeled next size est.range $1.5M$3.6M
1.6×
Last step-up
$20.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Craig Lang1 other2016-08
Cristopher Grunewald2014-07
John Krohn2016-08
WIlliam Pim2015-07
Registry & provenance

Spotlight Innovation, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1388486
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Transposon Therapeutics, Inc.PharmaceuticalsSeries C$59.1M$40.6Msame sector · same stage
Retym, Inc.Other TechnologySeries C$40.4M$531.3Mnetwork1 shared operator · same stage
Allena Pharmaceuticals, Inc.PharmaceuticalsSeries C$80.5M$75.1Msame sector · same stage
Cortexyme, Inc.PharmaceuticalsSeries C$111.5M$72.0Msame sector · same stage
Cosmos Health Inc.PharmaceuticalsSeries B$44.3M$53.4Msame sector
Actuate Therapeutics, Inc.PharmaceuticalsSeries C$127.5M$29.0Msame sector · same stage
Kitov Pharma Ltd.PharmaceuticalsSeries A$42.6M$23.2Msame sector
Diffusion Pharmaceuticals Inc.PharmaceuticalsSeries C$140.0M$26.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Spotlight Therapeutics, Inc.BiotechnologySeries B$688.5M91%
Bright Path Laboratories, Inc.PharmaceuticalsSeries A$150.2M81%
Innovate Biopharmaceuticals Inc.PharmaceuticalsSeries B$1.1B81%
Innovate Biopharmaceuticals, Inc.PharmaceuticalsSeries C$791.8M81%
IntelGenx Technologies Corp.PharmaceuticalsSeed$7.1M80%
OptiNose, Inc.PharmaceuticalsSeries B$34.7M80%
Response Pharmaceuticals, Inc.PharmaceuticalsSeries A$20.5M80%
Innovative Med Concepts, LLCPharmaceuticalsSeries A$3.6M79%
Frequently asked
How much funding has Spotlight Innovation, Inc. raised?
Spotlight Innovation, Inc. has raised approximately $44.1M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Spotlight Innovation, Inc.'s estimated valuation?
Provath's modeled valuation for Spotlight Innovation, Inc. is approximately $48.5M (modeled range $4.5M–$127.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Spotlight Innovation, Inc. at?
Spotlight Innovation, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Wed Aug 31.
What does Spotlight Innovation, Inc. do and where is it based?
Spotlight Innovation, Inc. operates in the Pharmaceuticals sector, based in West Des Moines.
Explore related

See where Spotlight Innovation, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Spotlight Innovation, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.